Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates
Bioorganic & Medicinal Chemistry Letters · 2023-07 · 91 · 129348
DOI: 10.1016/j.bmcl.2023.129348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2023-07. Verfasst von Michael G Brant und 10 weiteren Autor:innen. Beteiligte Einrichtung: ADC Therapeutic Development, Zymeworks Inc., Vancouver, BC, Canada. Electronic address: michael.brant@zymeworks.com. Hauptthemen laut MEDLINE: Immunoconjugates, Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Pairing immunostimulatory small molecules with the targeting capability of an antibody has emerged as a novel therapeutic modality with the potential to treat a variety of solid tumors. A series of compounds based on an imidazo-thienopyridine scaffold were synthesized and tested for their ability to agonize the innate immune sensors toll-like receptor 7 and 8 (TLR7/8). Structure-activity relationship (SAR) studies revealed that certain simple amino-substituents could enable TLR7 agonism at low nanomolar concentrations. Drug-linkers containing either payload 1 or 20h were conjugated to the HER2-targeting antibody trastuzumab at the interchain disulfide cysteine residues using a cleavable valine-citrulline dipeptide linker and stochastic thiol-maleimide chemistry. In vitro, these immune-stimulating antibody drug-conjugates (ADCs) were found to induce cytokine release in a murine splenocyte assay when co-cultured with the HER2-high NCI-N87 cancer cell line. In vivo, tumor regression was observed with a single dose in an NCI-N87 gastric carcinoma xenograft model in BALB/c nude mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ADC Therapeutic Development, Zymeworks Inc., Vancouver, BC, Canada. Electronic address: michael.brant@zymeworks.com.
- ADC Therapeutic Development, Zymeworks Inc., Vancouver, BC, Canada.
- ADC Therapeutic Development, Zymeworks Inc., Vancouver, BC, Canada. Electronic address: stuart.barnscher@zymeworks.com.
Zitieren
APA
Brant, M. G., Garnett, G. A. E., Guedia, J., Lasalle, M., Lawn, S., Petersen, M. E., Duan, R., Mendez-Campos, J., Hirkala-Schaefer, T., Winters, G. C., & Barnscher, S. D. (2023). Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates. Bioorganic & Medicinal Chemistry Letters, 91, 129348. https://doi.org/10.1016/j.bmcl.2023.129348
Vancouver
Brant MG, Garnett GAE, Guedia J, Lasalle M, Lawn S, Petersen ME, et al. Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates. Bioorganic & Medicinal Chemistry Letters. 2023;91:129348. doi:10.1016/j.bmcl.2023.129348
BibTeX
@article{Brant2023,
author = {Brant, Michael G and Garnett, Graham A E and Guedia, Joy and Lasalle, Manuel and Lawn, Samuel and Petersen, Mark E and Duan, Renee and Mendez-Campos, José and Hirkala-Schaefer, Truman and Winters, Geoffrey C and Barnscher, Stuart D},
title = {Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2023},
volume = {91},
pages = {129348},
doi = {10.1016/j.bmcl.2023.129348}
}
EUVIMED